Journal of Chemotherapy · 1995 · 35 citations · 24 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMedical OncologyAlkylating AgentsChemotherapy In Hematologic MalignanciesChemotherapy ResistanceCytotoxic ChemotherapyHematologic Malignancy TherapyOncology PharmacologyAcute Myeloid Leukemia TherapyAlkylating Agent ResistancePilot Study DesignPlatinum-based AgentsPlatinum-based CombinationsPlatinum-based RegimensTemozolomide TherapyTumor Resistance
High levels of O6-alkylguanine-DNA-alkyltransferase (OGAT) can, at least in part, account for tumor cell resistance to O6-alkylguanine alkylating agents, including triazene compounds. A pilot clinical study indicates that dacarbazine can induce a marked decrease of leukemic blasts in patients affected by acute myelogenous leukemia (AML) with low pretreatment levels of OGAT activity. In this study we show a synergistic antitumor effect between cisplatin (CDDP) and temozolomide (an in vitro active analog of dacarbazine), following combined in vitro treatment of leukemic blasts. Synergistic effect appears to be CDDP-dose dependent. In vivo treatment of leukemic patients with CDDP was followed by a reduction of OGAT activity in 2 out 3 cases. These data point out that CDDP could be a good candidate for depleting OGAT protein of leukemic cells, thus reversing tumor cell resistance to dacarbazine.
24
Platinum Compounds: a New Class of Potent Antitumour Agents
Barnett Rosenberg, Loretta Vancamp, James E. Trosko et al. · Nature · 1969 · 3.9K citations
M. Eileen Dolan, Robert C. Moschel, Anthony E. Pegg · Proceedings of the National Academy of Sciences · 1990 · 461 citations
Medicine, Oncology, Pharmacology +9